BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 21684428)

  • 1. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
    Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
    Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pandemic influenza vaccine in India: from strain to sale within 12 months.
    Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S
    Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic.
    Surichan S; Wirachwong P; Supachaturas W; Utid K; Theerasurakarn S; Langsanam P; Lakornrach P; Nitisaporn L; Chansikkakorn C; Vangkanonta W; Kaweepornpoj R; Poopipatpol K; Thirapakpoomanunt S; Srichainak S; Artavatkun W; Chokevivat V; Wibulpolprasert S
    Vaccine; 2011 Jul; 29 Suppl 1():A29-33. PubMed ID: 21684425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets.
    Pearce MB; Belser JA; Houser KV; Katz JM; Tumpey TM
    Vaccine; 2011 Apr; 29(16):2887-94. PubMed ID: 21338676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
    Rudenko L; Isakova-Sivak I
    Expert Rev Vaccines; 2015 Mar; 14(3):395-412. PubMed ID: 25555687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J; Ambrose CS; Dickinson S; Hamilton H; Oleka NA; Malinoski FJ; Wittes J
    Vaccine; 2009 Feb; 27(7):1101-10. PubMed ID: 19095024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
    Stittelaar KJ; Veldhuis Kroeze EJ; Rudenko L; Dhere R; Thirapakpoomanunt S; Kieny MP; Osterhaus AD
    Vaccine; 2011 Nov; 29(49):9265-70. PubMed ID: 21945964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
    Friede M; Palkonyay L; Alfonso C; Pervikov Y; Torelli G; Wood D; Kieny MP
    Vaccine; 2011 Jul; 29 Suppl 1():A2-7. PubMed ID: 21684422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets.
    Yang P; Duan Y; Wang C; Xing L; Gao X; Tang C; Luo D; Zhao Z; Jia W; Peng D; Liu X; Wang X
    Vaccine; 2011 Jan; 29(4):698-705. PubMed ID: 21111782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
    George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
    Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
    Abelin A; Colegate T; Gardner S; Hehme N; Palache A
    Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.